Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
NCT06482112 on ClinicalTrials.gov · last registry update 2026-06-01
Finished 27 June 2025, after enrolling 124 people. Primary outcome, as filed: Mean Relative Reduction From Baseline in Liver Fat Content at Week 28. efinopegdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- efinopegdutide
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Enrollment
- 124
- Started
- 2024-07-29
- Primary completion
- 2025-06-27 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean Relative Reduction From Baseline in Liver Fat Content at Week 28
Conditions studied
Metabolic Dysfunction-Associated Steatotic Liver Disease · Non-alcoholic Fatty Liver Disease · Nonalcoholic Fatty Liver Disease · Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the efinopegdutide page for this molecule’s full trial and approval history.